Obamacare enrollment to open this spring for people losing Medicaid after pandemic protections end

Obamacare enrollment to open this spring for people losing Medicaid after pandemic protections end


Millions of people in the U.S. are at risk of losing Medicaid this year when coverage protections put in place during the Covid-19 pandemic come to an end in April.

To make it easier for these individuals to transition to other coverage, the Health and Human Services Department has announced a special enrollment period for Obamacare.

People who lose Medicaid coverage from March 31 through July 31, 2024 can apply for Obamacare outside of the normal enrollment period at healthcare.gov if they live in a state served by the federal marketplace, according to new guidance from HHS.

A majority of the states, 33 in total, use healthcare.gov as their insurance marketplace. The 17 states that run their own marketplaces can implement a special enrollment period but are not required to do so.

Individuals who lose Medicaid won’t have to provide any additional documentation to shop for Obamacare. The application will simply ask them whether they lost Medicaid coverage.

Consumers have 60 days to pick a health insurance plan after submitting their application. Once they’ve picked a new plan, coverage will begin on the first day of the following month.

Typically, consumers have to submit documentation of a life change to apply for health insurance outside the open enrollment period, but HHS is streamlining the process for those losing Medicaid.

Medicaid enrollment swelled during the pandemic after Congress basically banned state governments from kicking people off the program for the duration of the public health emergency.

Enrollment in Medicaid has increased by 28% since February 2020 to nearly 84 million people as of September, according to the Center for Medicare and Medicaid Services.

Congress passed a federal spending bill in December that separated the Medicaid coverage protections from the public health emergency. States can start withdrawing coverage for people in April if they no longer meet eligibility criteria or are unresponsive to information requests.

HHS has estimated that 15 million people will lose Medicaid coverage once the pandemic-coverage protections end. Eight million of them will need to transition to other forms of coverage, according to HHS estimates. But 6.8 million will lose Medicaid despite still being eligible for the program, according to HHS.

States are required to make a good faith effort to contact the individual whose eligibility is under review through more than one communication method.



Source

Abortion pill makers brace for restrictions a year after Trump’s election
Health

Abortion pill makers brace for restrictions a year after Trump’s election

Mifepristone and Misoprostol pills are pictured Wednesday, Oct. 3, 2018, in Skokie, Illinois. Erin Hooley | Chicago Tribune | Tribune News Service | Getty Images Just over a year since Donald Trump was elected president again, the $6.9 billion abortion pill industry is operating under the same federal rules he inherited from former President Joe […]

Read More
Republicans push Obamacare tax credit alternatives as enrollment deadline looms
Health

Republicans push Obamacare tax credit alternatives as enrollment deadline looms

An Obamacare sign is displayed outside an insurance agency on Nov. 12, 2025 in Miami, Florida. Joe Raedle | Getty Images With enhanced Obamacare tax credits set to expire at the end of the year, Republicans are proposing new alternatives aimed at lowering the cost of health care. Their window for doing so is rapidly […]

Read More
Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target
Health

Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target

The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the […]

Read More